Original from: genomeweb

Singlera Genomics and its partner Breakthrough Genomics this week announced a research collaboration with the University of Pittsburgh around the early detection of pancreatic cancer.

Under the collaboration, the parties will run a preclinical study evaluating Singlera and Breakthrough's BT-Reveal Early Pancreatic Cancer Test.

Financial and other terms of the agreement were not disclosed.

The BT-Reveal blood test uses La Jolla, California-based Singlera's mTitan platform to analyze methylation patterns in cell-free DNA. The test has received breakthrough device designation from the US Food and Drug Administration and is currently available for high-risk patients as a laboratory-developed test offered by Irvine, California-based Breakthrough, which operates a CAP- and CLIA-certified laboratory.

"We are excited to partner with the top pancreatic cancer researchers in the field to study the efficacy and impact of pancreatic cancer screening in high-risk populations," Singlera Chief Operating Officer and Cofounder Qiang Liu said in a statement. "This preclinical study with Pitt is an important step towards a full large-scale FDA longitudinal study; we hope that the BT-Reveal test based on Singlera’s advanced methylation technology can give clinicians an important tool to allow faster screening and treatment of high-risk patients."

Source: Singlera, Breakthrough Genomics Collaborating With U Pitt on Early Detection of Pancreatic Cancer